AmerisourceBergen Corp. (NYSE:ABC) has been assigned a consensus recommendation of “Hold” from the ten research firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $89.67.
Several analysts have issued reports on ABC shares. TheStreet upgraded shares of AmerisourceBergen from a “c+” rating to a “b-” rating in a research note on Friday, December 6th. ValuEngine cut shares of AmerisourceBergen from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Finally, Argus reiterated a “buy” rating and issued a $110.00 target price on shares of AmerisourceBergen in a research note on Monday, November 18th.
NYSE ABC traded down $0.31 on Thursday, hitting $91.06. The stock had a trading volume of 565,269 shares, compared to its average volume of 869,136. AmerisourceBergen has a 52-week low of $70.55 and a 52-week high of $94.75. The company has a debt-to-equity ratio of 1.45, a quick ratio of 0.58 and a current ratio of 0.95. The company has a market capitalization of $18.29 billion, a price-to-earnings ratio of 12.84, a price-to-earnings-growth ratio of 1.59 and a beta of 0.96. The firm has a 50-day moving average of $86.16 and a 200-day moving average of $85.94.
AmerisourceBergen (NYSE:ABC) last posted its earnings results on Thursday, November 7th. The company reported $1.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.03. AmerisourceBergen had a net margin of 0.48% and a return on equity of 48.84%. The business had revenue of $45.64 billion for the quarter, compared to analysts’ expectations of $45.15 billion. During the same period in the prior year, the company posted $1.45 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, research analysts anticipate that AmerisourceBergen will post 7.52 earnings per share for the current fiscal year.
In other news, EVP Gina Clark sold 10,917 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $88.24, for a total transaction of $963,316.08. Also, CEO Steven H. Collis sold 19,905 shares of AmerisourceBergen stock in a transaction on Monday, November 4th. The stock was sold at an average price of $86.08, for a total transaction of $1,713,422.40. Following the completion of the transaction, the chief executive officer now owns 154,484 shares in the company, valued at approximately $13,297,982.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,724 shares of company stock worth $5,561,840. Corporate insiders own 27.80% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Pathstone Family Office LLC grew its holdings in AmerisourceBergen by 67.7% in the 2nd quarter. Pathstone Family Office LLC now owns 312 shares of the company’s stock worth $27,000 after acquiring an additional 126 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of AmerisourceBergen during the 3rd quarter valued at about $27,000. Transamerica Financial Advisors Inc. bought a new stake in shares of AmerisourceBergen during the 2nd quarter valued at about $38,000. FinTrust Capital Advisors LLC boosted its stake in shares of AmerisourceBergen by 27.5% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 571 shares of the company’s stock valued at $47,000 after purchasing an additional 123 shares in the last quarter. Finally, Citizens Financial Group Inc RI boosted its stake in shares of AmerisourceBergen by 28.0% during the 3rd quarter. Citizens Financial Group Inc RI now owns 581 shares of the company’s stock valued at $47,000 after purchasing an additional 127 shares in the last quarter. Institutional investors own 66.74% of the company’s stock.
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.